|Bid||3.90 x 4000|
|Ask||5.63 x 2900|
|Day's Range||4.17 - 4.34|
|52 Week Range||3.64 - 7.00|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 8, 2018 - May 14, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||11.20|
On Thursday, July 12, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. All sectors ended Wednesday's trading session in bullish territories. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Biotechnology equities this morning: Infinity Pharmaceuticals Inc. (NASDAQ: INFI), Innoviva Inc. (NASDAQ: INVA), Inovio Pharmaceuticals Inc. (NASDAQ: INO), and Insmed Inc. (NASDAQ: INSM).
Inovio Pharmaceuticals, Inc. (INO) today announced positive Phase 1 results of its collaborative vaccine study with INO-4700 (GLS-5300) against MERS (Middle East Respiratory Syndrome). Results for INO-4700, which is being co-developed by Inovio and GeneOne Life Science Inc. (KSE:011000), showed that the drug was well-tolerated and demonstrated overall high levels of antibody responses in roughly 95% of subjects, while also generating broad-based T cell responses in nearly 90% of study participants. The Phase 1, open-label, dose-escalation MERS vaccine trial, in partnership with the Walter Reed Army Institute of Research in Maryland, displayed antibody responses by ELISA in 94% of subjects at week 14 (two weeks post-third dose).
Inovio Pharmaceuticals, Inc. (INO) today announced that it has dosed its first patient as part of its Phase 1/2 immuno-oncology trial in patients with newly diagnosed glioblastoma (GBM). The efficacy trial is designed to evaluate Inovio’s INO-5401 T cell activating immunotherapy encoding multiple antigens expressed by GBM and INO-9012, an immune activator encoding IL-12, in combination with cemiplimab (REGN2810), a PD-1 inhibitor developed by Regeneron Pharmaceuticals. Dr. J. Joseph Kim, Inovio's President and Chief Executive Officer, said, “GBM is a devastating cancer, and malignant glioma has already claimed the lives of Senator Ted Kennedy and Beau Biden, the son of the former Vice President Joe Biden.
Inovio (INO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
PLYMOUTH MEETING, Pa., May 31, 2018-- Inovio Pharmaceuticals, Inc. today announced that Dr. J. Joseph Kim, President and CEO, will address Inovio’ s ability to respond to emerging viral threats at the ...
Inovio Pharmaceuticals, Inc. (INO) today announced that it has bolstered its efforts to attract partnerships and collaborations and increase non-dilutive funding with the hiring of an accomplished business development leader and the promotion of a key R&D leader. Mr. Shawn D. Bridy joins Inovio as Vice President of Business Development reporting to Dr. J. Joseph Kim, President & CEO. Mr. Bridy has more than 20 years of business development & licensing, commercial strategy, and transaction experience in the life sciences industry.
Inovio (INO) begins a phase II study to evaluate the efficacy of its pipeline candidate VGX-3100 on adult men and women with human papilloma virus (HPV)-related anal dysplasia.
Inovio Pharmaceuticals, Inc. (INO) today announced that it has commenced a Phase 2 clinical trial to evaluate the efficacy of VGX-3100 in adult men and women with human papilloma virus (HPV)-related anal dysplasia. Recruitment is ongoing for patients who are HIV-negative with histologically confirmed anal or perianal high-grade squamous intraepithelial lesions (HSIL) associated with HPV-16 and/or HPV-18. Anal HSIL or dysplasia is the precursor to anal cancer, which is estimated to cause more than 1,100 deaths in the United States in 2018.
PLYMOUTH MEETING, Pa., May 17, 2018-- Inovio Pharmaceuticals, Inc. today announced a poster presentation of additional prostate cancer data at the American Society of Clinical Oncology annual meeting to ...
NEW YORK, NY / ACCESSWIRE / May 16, 2018 / Shares of biotech stocks Heat Biologics and Inovio Pharmaceuticals both saw gains in Tuesday's trading session. It was a positive data update on Inovio's HIV ...
Inovio Pharmaceuticals, Inc. (INO) today announced that its HIV vaccine, PENNVAX®-GP, maintained durable and robust immune responses at month 12, a full six months after the last dose in a Phase 1 clinical study. Inovio previously reported that PENNVAX-GP elicited the highest overall levels of immune response rates (cellular and humoral) ever demonstrated in a human study by an HIV vaccine. To potentially prevent and treat HIV, PENNVAX-GP consists of a combination of four HIV antigens designed to generate both antibody and T-cell responses and cover multiple global HIV strains.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on May 9) ABIOMED, Inc. (NASDAQ: ABMD ) Adaptimmune Therapeutics PLC – ...
The Plymouth Meeting, Pennsylvania-based company said it had a loss of 36 cents per share. The drugmaker posted revenue of $1.5 million in the period. In the final minutes of trading on Wednesday, the ...
PLYMOUTH MEETING, Pa., May 09, 2018-- Inovio Pharmaceuticals, Inc., a late-stage biotechnology company focused on the discovery, development, and commercialization of DNA immunotherapies targeted against ...
After eking out a modest gain in the week ended April 27, the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB) pulled back this week amid some not-so-encouraging earnings reports and negative regulatory ...
Inovio's (INO) most advanced pipeline candidate, VGX-3100's progress remains in focus. However, lack of an approved product in the company's portfolio is a dampener.
PLYMOUTH MEETING, Pa., April 30, 2018-- Inovio Pharmaceuticals, Inc. announced today that it will host a conference call and live webcast to report its 2018 first quarter financial results on Wednesday, ...